Harith Rajagopalan, Fractyl Health CEO
Betting on public market demand for more obesity therapies, Fractyl Health files for IPO to back gene therapy
A week after one obesity biotech, Carmot Therapeutics, backed out of its IPO plans in favor of a $2.7 billion sale to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
